News articles about NxStage Medical (NASDAQ:NXTM) have trended somewhat positive on Sunday, according to Accern Sentiment. The research group rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. NxStage Medical earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned media coverage about the medical device company an impact score of 46.1128372429892 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

A number of analysts have recently commented on the company. BidaskClub lowered NxStage Medical from a “buy” rating to a “hold” rating in a research note on Friday, July 20th. Zacks Investment Research lowered NxStage Medical from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, ValuEngine raised NxStage Medical from a “hold” rating to a “buy” rating in a research note on Friday, July 6th. One analyst has rated the stock with a sell rating and five have issued a hold rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $30.00.

Shares of NxStage Medical traded up $0.04, reaching $28.30, during mid-day trading on Friday, according to MarketBeat. 245,504 shares of the company were exchanged, compared to its average volume of 423,271. NxStage Medical has a 52 week low of $22.70 and a 52 week high of $29.39. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of -128.64 and a beta of 0.02.

NxStage Medical (NASDAQ:NXTM) last issued its quarterly earnings data on Thursday, May 10th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.02 by ($0.04). NxStage Medical had a negative return on equity of 6.85% and a negative net margin of 3.67%. The company had revenue of $107.30 million for the quarter, compared to the consensus estimate of $106.95 million. research analysts predict that NxStage Medical will post -0.02 EPS for the current fiscal year.

NxStage Medical Company Profile

NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.

Further Reading: Diversification in Investing

Insider Buying and Selling by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with's FREE daily email newsletter.